Results are demonstrated first on the effects of GLP-1 on rewarding behaviors, secondly, its neuroanatomical explanations, and lastly, molecular mechanisms
Given the study did not show a significant difference in fibrosis stage, semaglutide has not yet been FDA approved for NASH
Yet studies show that people who achieve up to 20% weight loss on these drugs often regain that weight quickly if they stop treatment
Tirzepatide (Zepbound In a 72-week study, people taking tirzepatide lost an average of ): 21% of their body weight
When was Victoza taken off the market
Furthermore, studies have examined these effects in fibroblast and keratinocyte cultures, endothelial and neuronal systems, and preclinical animal models related to wound repair and tissue response